| Unit 1 |
1. What is Clinical Research (CR) and its significance(CR) |
| Unit 2 |
1.2 Phases of Drug Development (Pre-clinical to Post-marketing)(CR) |
| Unit 3 |
1.3 Types of Clinical Trials (Interventional vs. Observational)(CR) |
| Unit 4 |
1.4 Key stakeholders in CR Sponsor, CRO, Investigator, IRBIEC, Regulatory Authorities(CR) |
| Unit 1 |
2.1 History and purpose of ICH GCP |
| Unit 2 |
2.2 The Core Principles of ICH E6(R3) |
| Unit 3 |
2.3. Quality_by_Design |
| Unit 4 |
2.4 QMS_in_Clinical_Trials |
| Unit 5 |
2.5 Training requirements and documentation within a QMS |
| Unit 1 |
3.1 Ethical Principles (Belmont Report, Declaration of Helsinki). |
| Unit 2 |
3.2 Principles of GCP Data integrity, records retention, proportionate procedures |
| Unit 3 |
3.3 Trial Processes and Measures being Proportionate to Risk.-Risk-Proportionate_Trials |
| Unit 4 |
3.4 Essential Documents for the Conduct of a Trial |
| Unit 1 |
4.1 Clinical Trials Protocol, Design, and Methodology |
| Unit 2 |
4.2 The Clinical Trial Protocol Components and Amendments |
| Unit 3 |
4.3 Trial Designs Parallel, Crossover, Factorial |
| Unit 4 |
4.4 Adaptive Clinical Trial Designs Concepts, Advantages, Challenges |
| Unit 5 |
4.5 Blinding and Randomization |
| Unit 1 |
5.1 Purpose, Composition, and Authority of the IRB & IEC |
| Unit 2 |
5.2 Types of Review (Full, Expedited, Exemption) |
| Unit 3 |
5.3 Continuing Review and Reporting Requirements |
| Unit 1 |
6.1 Investigator's Role and Responsibilities |
| Unit 2 |
6.2 Communication with the IRB_IEC |
| Unit 3 |
6.3 Global Regulatory Bodies |
| There are no units in this module. |